CLINICAL SIGNIFICANCE OF BIOMARKERS IN OVARIAN CANCER, PROSTATE CANCER, COLORECTAL CANCER
https://doi.org/10.17709/2409-2231-2016-3-1-7
Abstract
The review is devoted to modern notions about serum tumor markers and their place in oncology: using for differential diagnosis, in prognosis of course of tumor process, during follow-up, for preclinical detection of disease recurrences, as well as in screening aimed at early detection of malignant neoplasms. Algorithms of using of most informative tumor markers: CA125, HE4 (in ovarian cancer), PSA and its isoforms (in prostate cancer), iFOBT (in colorectal cancer) were described.
Keywords
serum tumor markers,
CA125,
HE4,
PSA,
free PSA,
[-2]proPSA,
iFOBT,
ovarian cancer,
prostate cancer,
colorectal cancer
About the Authors
N. V. Marshutina
P. Hertsen Moscow Oncology Research Institute – b ranch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (Moscow, Russia) 3, 2nd Botkinskiy proezd, Moscow, 125284, Russia
Russian Federation
Russian Federation
PhD, senior researcher, department of forecast of the effectiveness of conservative treatment
M. P. Solokhina
P. Hertsen Moscow Oncology Research Institute – b ranch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (Moscow, Russia) 3, 2nd Botkinskiy proezd, Moscow, 125284, Russia
Russian Federation
Russian Federation
PhD, researcher, department of forecast of the effectiveness of conservative treatment
I. I. Alentov
P. Hertsen Moscow Oncology Research Institute – b ranch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (Moscow, Russia) 3, 2nd Botkinskiy proezd, Moscow, 125284, Russia
Russian Federation
Russian Federation
junior researcher, department of forecast of the effectiveness of conservative treatment
N. S. Sergeeva
P. Hertsen Moscow Oncology Research Institute – b ranch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (Moscow, Russia) 3, 2nd Botkinskiy proezd, Moscow, 125284, Russia
FBEI HPE "Pirogov Russian National Research Medical University" the Ministry of Health of the Russian Federation (Moscow, Russia) 1, ul. Ostrovityanova, Moscow, 117997, Russia
Russian Federation
Russian Federation
Professor, Dr. Sci. (Biol.),, head of the department of forecast of the effectiveness of conservative treatment, P. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, professor of biological department, medical-biological faculty of FBEI HPE "Pirogov Russian National Research Medical University" the Ministry of Health of the Russian Federation
References
1. Duffi M. J. How to validate a new cancer biomarker: from discovery to clinical application. Tumor Biology. 2014; 35 (1): 5.
2. Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.
3. Moghadam A. F., Stieber P. Sensible use of tumor markers. 2nd ed. Basel, Jurgen-Hartmann Verlag. 1993.
4. Marshutina N. V., Sergeeva N. S. Serologicheskie opukholevye markery v pervichnoi diagnostike i monitoringe bol'nykh rakom molochnoi zhelezy. Rossiiskii onkologicheskii zhurnal. 2002; 4: 45–48. (Russian).
5. Practice Guidelines and Recommendation for use of Tumor Markers in the Clinic. The Natl. Acad. Clin. Biochem. 2002; 15; 1–56.
6. Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.
7. Sergeeva N. S., Rusakov I. G., Marshutina N. V., Rodina I. A., Akhmedova I. It., Kirsanova V. A., Makhmurova N. Т., Sergeeva V. S. Examination of a serological tumor marker Tu M2‑PK in patients with renal carcinoma. Rossiiskii onkologicheskii zhurnal. 2005; 3: 30–32. (Russian).
8. Sergeeva N. S., Marshutina N. V. Serologicheskie opukholeassotsiirovannye markery. In: Chissov V. I., Davydov M.I (eds.). Onkologiya. Natsional'noe rukovodstvo. Moscow: "GEOTAR- media" Publ., 2008. (Russian).
9. Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).
10. Berezhnaya N. M., Chekhun V. F. Immunologiya zlokachestvennogo rosta. Kiev: "Naukova dumka" Publ., 2005. (Russian).
11. Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells (review). In: Critical Reviews in Oncogenesis, CRC-Press, Boca Raton, Florida. (M. Perucho, ed.). 1992; 3 (1, 2): 91–115.
12. Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).
13. He Q., Zhang J., Zou S., Li H., Wang X., Zhou S., Fornander T., Skog S. Concentration of tymidine kinase 1 (S‑TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005; 14 (4): 1013–1019.
14. Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.
15. Duffi M. J. How to validate a new cancer biomarker: from discovery to clinical application. Tumor Biology. 2014; 35 (1): 5.
16. Hardardottir H., Parmley T. H., Quirk J. G. Jr., Sanders M. M., Miller F. C., O'Brien T. J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am. J. Obstet. Gynecol. 1990; 163 (6. Pt 1):1925–1931.
17. Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;
18. Marshutina N. V., Sergeeva N. S. Serologicheskie opukholevye markery v pervichnoi diagnostike i monitoringe bol'nykh rakom molochnoi zhelezy. Rossiiskii onkologicheskii zhurnal. 2002; 4: 45–48. (Russian).
19. Gipson I. K., Blalock T., Tisdale A., Spurr-Michaud S., Allcorn S., Stavreus-Evers A., Gemzell K. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Bio Reprod. 2008; 78 (1): 134–142.
20. 50 (6): 1017–1025.
21. Sergeeva N. S., Rusakov I. G., Marshutina N. V., Rodina I. A., Akhmedova I. It., Kirsanova V. A., Makhmurova N. Т., Sergeeva V. S. Examination of a serological tumor marker Tu M2‑PK in patients with renal carcinoma. Rossiiskii onkologicheskii zhurnal. 2005; 3: 30–32. (Russian).
22. Gubbels J. A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T. K., Connor J., Sathyanarayana B. K., Lee B., Pastan I., Patankar M. S. Mesothelin-MUC16 binding is a high affinity, N‑glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5 (1): 50.
23. Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.
24. Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells (review). In: Critical Reviews in Oncogenesis, CRC-Press, Boca Raton, Florida. (M. Perucho, ed.). 1992; 3 (1, 2): 91–115.
25. Gubbels J. A., Felder M., Horibata S., Belisle J. A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J. P., Patankar M. S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer. 2010. 20; 9: 11.
26. He Q., Zhang J., Zou S., Li H., Wang X., Zhou S., Fornander T., Skog S. Concentration of tymidine kinase 1 (S‑TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005; 14 (4): 1013–1019.
27. Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.
28. Nguyen H. N., Jacobson A., Patino–Paul R. New reference levels for CA125 in pre-and postmenopau-sal women. Prim Care Update Ob Gyns. 1998; 5 (4):157.
29. Hardardottir H., Parmley T. H., Quirk J. G. Jr., Sanders M. M., Miller F. C., O'Brien T. J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am. J. Obstet. Gynecol. 1990; 163 (6. Pt 1):1925–1931.
30. Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.
31. Sturgeon C. M., Duffy M. J., Stenman U. H. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54 (12): 11–79.
32. Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4
33. Gipson I. K., Blalock T., Tisdale A., Spurr-Michaud S., Allcorn S., Stavreus-Evers A., Gemzell K. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Bio Reprod. 2008; 78 (1): 134–142.
34. Jacobs I., Bast R. C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4 (1): 1–12.
35. Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).
36. Gubbels J. A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T. K., Connor J., Sathyanarayana B. K., Lee B., Pastan I., Patankar M. S. Mesothelin-MUC16 binding is a high affinity, N‑glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5 (1): 50.
37. Tuxen M. K. Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol. 2001; 16 (1): 49–67.
38. Gubbels J. A., Felder M., Horibata S., Belisle J. A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J. P., Patankar M. S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer. 2010. 20; 9: 11.
39. Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.
40. Kobayashi E., Ueda Y., Matsuzaki S., Yokoyama T., Kimura T., Yoshino K., Fujita M., Kimura T., Enomoto T. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21 (11): 1902–1912.
41. Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.
42. Nguyen H. N., Jacobson A., Patino–Paul R. New reference levels for CA125 in pre-and postmenopau-sal women. Prim Care Update Ob Gyns. 1998; 5 (4):157.
43. Akhmedova S. A. Sovershenstvovanie kliniko-laboratornoi kontseptsii ispol'zovaniya SA 125 u bol'nykh rakom yaichnikov: Dis. … kand. biol. nauk: 14.00.14. Mosсow, 2003. (Russian).
44. Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.
45. Sturgeon C. M., Duffy M. J., Stenman U. H. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54 (12): 11–79.
46. Topalak O., Saygili U., Soyturk M., Karaca N., Batur Y., Uslu T., Erten O. Serum, pleural effusion, and ascites CA‑125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002; 85 (1):108–113.
47. Jacobs I., Bast R. C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4 (1): 1–12.
48. Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.
49. Sölétormos G., Duffy M. J., Othman Abu Hassan S., Verheijen R. H., Tholander B., Bast R. C. Jr., Gaarenstroom K. N., Sturgeon C. M., Bonfrer J. M., Petersen P. H., Troonen H., Carlo-Torre G., Kanty Kulpa J., Tuxen M. K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer. 2016; 26 (1): 43–51.
50. Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.
51. Tuxen M. K. Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol. 2001; 16 (1): 49–67.
52. Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995; 86 (2): 259–264.
53. Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.
54. Kobayashi E., Ueda Y., Matsuzaki S., Yokoyama T., Kimura T., Yoshino K., Fujita M., Kimura T., Enomoto T. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21 (11): 1902–1912.
55. Korneyeva I. A., Novikova Ye. G., Sergeyeva N. S. Present views of the marker recurrence of ovarian cancer. Rossiiskii onkologicheskii zhurnal. 2010; 2: 54–7. (Russian).
56. Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.
57. Akhmedova S. A. Sovershenstvovanie kliniko-laboratornoi kontseptsii ispol'zovaniya SA 125 u bol'nykh rakom yaichnikov: Dis. … kand. biol. nauk: 14.00.14. Mosсow, 2003. (Russian).
58. Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon M. F. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol. 2007; 18 (5): 881–885.
59. European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.
60. Topalak O., Saygili U., Soyturk M., Karaca N., Batur Y., Uslu T., Erten O. Serum, pleural effusion, and ascites CA‑125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002; 85 (1):108–113.
61. Liu P. Y., Alberts D. S., Monk B. J., Brady M., Moon J., Markman M. An early signal of CA‑125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25 (24): 3615–3620.
62. Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.
63. Sölétormos G., Duffy M. J., Othman Abu Hassan S., Verheijen R. H., Tholander B., Bast R. C. Jr., Gaarenstroom K. N., Sturgeon C. M., Bonfrer J. M., Petersen P. H., Troonen H., Carlo-Torre G., Kanty Kulpa J., Tuxen M. K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer. 2016; 26 (1): 43–51.
64. Aebi S., Castiglione M; ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 4: 21–23.
65. Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).
66. Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995; 86 (2): 259–264.
67. Guppy A. E., Rustin G. J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002; 7 (5): 437–443.
68. Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.
69. Korneyeva I. A., Novikova Ye. G., Sergeyeva N. S. Present views of the marker recurrence of ovarian cancer. Rossiiskii onkologicheskii zhurnal. 2010; 2: 54–7. (Russian).
70. Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann. Oncol. 2007; 18 (5): 881–885.
71. Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon M. F. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol. 2007; 18 (5): 881–885.
72. Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.
73. Sergeeva N. S., Marshutina N. V., Alentov I. I., Korneeva I. A., Novikova E. G. Serum tumor markers СА125 and НЕ4 in ovary cancer patients. Voprosy oncologii. 2013; 59 (2): 12–21. (Russian).
74. Liu P. Y., Alberts D. S., Monk B. J., Brady M., Moon J., Markman M. An early signal of CA‑125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25 (24): 3615–3620.
75. Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).
76. Khokhlova S. V. Individualizatsiya lecheniya bol'nykh rakom yaichnikov: Avtoref. diss. … dokt. med. nauk: 14.01.12/FGBNU «RONTs im. N. N. Blokhina». Moscow, 2015. (Russian).
77. Aebi S., Castiglione M; ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 4: 21–23.
78. Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.
79. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45 (2):350–357.
80. Guppy A. E., Rustin G. J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002; 7 (5): 437–443.
81. Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).
82. Galgano M. T., Hampton G. M., Frierson H. F. Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19 (6): 847–853.
83. Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.
84. Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann. Oncol. 2007; 18 (5): 881–885.
85. Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33 (1): 141–148.
86. De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.
87. Sergeeva N. S., Marshutina N. V., Alentov I. I., Korneeva I. A., Novikova E. G. Serum tumor markers СА125 and НЕ4 in ovary cancer patients. Voprosy oncologii. 2013; 59 (2): 12–21. (Russian).
88. Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57 (11): 1534–1544.
89. Khokhlova S. V. Individualizatsiya lecheniya bol'nykh rakom yaichnikov: Avtoref. diss. … dokt. med. nauk: 14.01.12/FGBNU «RONTs im. N. N. Blokhina». Moscow, 2015. (Russian).
90. Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.
91. Molina R., Escudero J. M., Augé J. M., Filella X., Foj L., Torné A., Lejarcegui J., Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32 (6): 1087–1095.
92. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45 (2):350–357.
93. Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012; 50 (12): 2181–2188.
94. Galgano M. T., Hampton G. M., Frierson H. F. Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19 (6): 847–853.
95. Macedo A. C., da Rosa M. I., Lumertz S., Medeiros L. R. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014; 24 (7): 1222–1231.
96. Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33 (1): 141–148.
97. Moore R. G., Brown A. K., Miller M. C., Skates S., Allard W. J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C. O., Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108 (2): 402–408.
98. Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57 (11): 1534–1544.
99. Anastasi E., Marchei G. G., Viggiani V., Gennarini G., Frati L., Reale M. G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31 (2): 113–119.
100. Molina R., Escudero J. M., Augé J. M., Filella X., Foj L., Torné A., Lejarcegui J., Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32 (6): 1087–1095.
101. Sergeeva N. S., Alentov I. I., Marshutina N. V., Korneeva I. A., Novikova E. G. Epididymis protein 4 as an additional serological marker for monitoring patients with ovarian cancer. Onkologiia. Zhurnal imeni P. A. Gerzena. 2014; 2 (2): 14–20. (Russian).
102. Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012; 50 (12): 2181–2188.
103. Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C. Jr, Skates S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009; 112 (1): 40–46.
104. Macedo A. C., da Rosa M. I., Lumertz S., Medeiros L. R. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014; 24 (7): 1222–1231.
105. Li J., Chen H., Mariani A., Chen D., Klatt E., Podratz K., Drapkin R., Broaddus R., Dowdy S., Jiang S. W. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci. 2013; 15; 14 (3): 6026–6043.
106. Moore R. G., Brown A. K., Miller M. C., Skates S., Allard W. J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C. O., Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108 (2): 402–408.
107. Ortiz-Muñoz B., Aznar-Oroval E., García García A., Covisa Peris A., Perez Ballestero P., Sanchez Yepes M., Garcia Lozano T., Illueca Ballester C., García Garcia E. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014; 35 (7): 7249–7258.
108. Anastasi E., Marchei G. G., Viggiani V., Gennarini G., Frati L., Reale M. G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31 (2): 113–119.
109. Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.
110. Sergeeva N. S., Alentov I. I., Marshutina N. V., Korneeva I. A., Novikova E. G. Epididymis protein 4 as an additional serological marker for monitoring patients with ovarian cancer. Onkologiia. Zhurnal imeni P. A. Gerzena. 2014; 2 (2): 14–20. (Russian).
111. Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.
112. Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C. Jr, Skates S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009; 112 (1): 40–46.
113. Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.
114. Li J., Chen H., Mariani A., Chen D., Klatt E., Podratz K., Drapkin R., Broaddus R., Dowdy S., Jiang S. W. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci. 2013; 15; 14 (3): 6026–6043.
115. Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.
116. Ortiz-Muñoz B., Aznar-Oroval E., García García A., Covisa Peris A., Perez Ballestero P., Sanchez Yepes M., Garcia Lozano T., Illueca Ballester C., García Garcia E. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014; 35 (7): 7249–7258.
117. Sergeeva N. S., Marshutina N. V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy. Prakticheskaya onkologiya. 2010; 11 (2): 110–119. (Russian).
118. Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.
119. Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.
120. Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.
121. Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.
122. Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.
123. Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.
124. Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.
125. Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.
126. Sergeeva N. S., Marshutina N. V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy. Prakticheskaya onkologiya. 2010; 11 (2): 110–119. (Russian).
127. Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.
128. Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.
129. Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.
130. Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.
131. Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).
132. Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.
133. Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).
134. Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.
135. Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.
136. Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.
137. Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;
138. Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.
139. 50 (6): 1017–1025.
140. Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).
141. Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.
142. Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).
143. Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.
144. Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.
145. Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.
146. Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;
147. Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4
148. 50 (6): 1017–1025.
149. Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).
150. Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.
151. Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.
152. Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.
153. Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.
154. Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.
155. Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.
156. Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4
157. Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.
158. Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).
159. Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.
160. Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.
161. Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.
162. Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.
163. Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.
164. Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.
165. European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.
166. Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.
167. Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.
168. Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.
169. Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).
170. Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.
171. Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.
172. Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.
173. Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.
174. European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.
175. Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).
176. Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.
177. Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.
178. Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).
179. Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).
180. Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.
181. Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.
182. Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.
183. De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.
184. Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).
185. Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.
186. Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.
187. Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).
188. Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.
189. De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.
190. Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.
Review
For citations:
Marshutina N.V., Solokhina M.P., Alentov I.I., Sergeeva N.S. CLINICAL SIGNIFICANCE OF BIOMARKERS IN OVARIAN CANCER, PROSTATE CANCER, COLORECTAL CANCER. Research and Practical Medicine Journal. 2016;3(1):46-57. (In Russ.) https://doi.org/10.17709/2409-2231-2016-3-1-7
Views:
1573
Email this article 